Replimune (REPL) Total Non-Current Liabilities (2018 - 2026)
Replimune (REPL) reported Total Non-Current Liabilities of $165.8 million for Q1 2026, up 23.21% on a YoY basis from $134.5 million in Q1 2025, and up 35.48% sequentially from $122.4 million in Q4 2025.
Replimune (REPL) Total Non-Current Liabilities (2018 - 2026) Analysis & Trends
Replimune (REPL) has 7 years of Total Non-Current Liabilities data on file, last reported at $165.8 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 23.21% year-over-year to $165.8 million; the trailing twelve-month figure through Mar 2026 stood at $165.8 million (up 23.21% YoY), and the FY2026 full-year result was $165.8 million, up 23.21% from the prior year.
- Total Non-Current Liabilities grew to $165.8 million in Q1 2026, from $122.4 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $165.8 million in Q1 2026 to a low of $50.0 million in Q1 2022.
- A 5-year average of $112.4 million and a median of $114.2 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities surged 81.79% in 2023 and gained 1.98% in 2025, its largest moves.
- Tracing REPL's Total Non-Current Liabilities over 5 years: stood at $50.0 million in 2022, then surged by 121.36% to $110.6 million in 2023, then climbed by 8.49% to $120.0 million in 2024, then increased by 1.98% to $122.4 million in 2025, then surged by 35.48% to $165.8 million in 2026.
- Business Quant data shows REPL's Total Non-Current Liabilities at $165.8 million in Q1 2026, $122.4 million in Q4 2025, and $125.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Replimune | 970.73 Mn | 970.73 Mn | - | 165.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 165.77 Mn |
| Dec 31, 2025 | 122.36 Mn |
| Sep 30, 2025 | 125.17 Mn |
| Jun 30, 2025 | 131.85 Mn |
| Mar 31, 2025 | 134.54 Mn |
| Dec 31, 2024 | 119.99 Mn |
| Sep 30, 2024 | 115.96 Mn |
| Jun 30, 2024 | 107.73 Mn |
| Mar 31, 2024 | 112.43 Mn |
| Dec 31, 2023 | 110.60 Mn |
| Sep 30, 2023 | 96.75 Mn |
| Jun 30, 2023 | 89.28 Mn |
| Mar 31, 2023 | 90.83 Mn |
| Mar 31, 2022 | 49.96 Mn |
| Mar 31, 2019 | 16.47 Mn |
| Dec 31, 2018 | 8.95 Mn |
| Sep 30, 2018 | 3.78 Mn |
| Jun 30, 2018 | 4.54 Mn |
| Mar 31, 2018 | 5.22 Mn |